Aurobindo Pharma completes sale of US subsidiary Natrol LLC to New Mountain Capital
New Delhi: Drug firm Aurobindo Pharma on Tuesday said it has completed the sale of Natrol LLC, a wholly-owned unit of its US-based subsidiary, to private equity firm New Mountain Capital.
In October this year, the company had announced that it had inked a pact to divest Natrol LLC to private equity firm New Mountain Capital for USD 550 million.
"The aforesaid transaction has been completed on November 30, 2020," Aurobindo Pharma said in a regulatory filing.
Aurobindo Pharma had acquired Natrol in December 2014.
"The aforesaid transaction has been completed on November 30, 2020," Aurobindo Pharma said in a regulatory filing.
Aurobindo Pharma had acquired Natrol in December 2014.
Natrol's annual sales for the 12 months ended March 31, 2020, stood at around USD 157 million.
Earlier, Aurobindo Pharma Managing Director N Govindarajan had said that proceeds from Natrol's divestiture will be used to reduce debt and other new strategic initiatives.
Read also: Aurobindo Pharma expects to commercialise vaccine facility by April-May 2021
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd